GT201300165A - Compuestos y su uso como inhibidores de bace - Google Patents

Compuestos y su uso como inhibidores de bace

Info

Publication number
GT201300165A
GT201300165A GT201300165A GT201300165A GT201300165A GT 201300165 A GT201300165 A GT 201300165A GT 201300165 A GT201300165 A GT 201300165A GT 201300165 A GT201300165 A GT 201300165A GT 201300165 A GT201300165 A GT 201300165A
Authority
GT
Guatemala
Prior art keywords
disease
cerebrial
dementia
heroe
alzheimer
Prior art date
Application number
GT201300165A
Other languages
English (en)
Inventor
Csjernyik Gabor
Karlström Sofia
Kers Annika
Kolmodin Karin
Nylöf Martin
Öhberg Liselotte
Rakos Laszlo
Sandberg Lars
Sehgelmeble Fernando
Söderman Peter
Swahn Britt-Marie
Von Berg Stefan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of GT201300165A publication Critical patent/GT201300165A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA (I) Y SUS COMPOSICIONES FARMACÉUTICAS. ADEMÁS, LA PRESENTE INVENCIÓN SE REFIERE A MÉTODOS TERAPÉUTICOS PARA EL TRATAMIENTO Y / O LA PREVENCIÓN DE PATOLOGÍAS RELACIONADAS CON EL SS COMO EL SÍNDROME, ANGIOPATÍA SS-AMILOIDE DE DOWN, TALES COMO, PERO NO LIMITADOS A ANGIOPATÍA AMILOIDE CEREBRAL O HEMORRAGIA CEREBRAL HEREDITARIA, TRASTORNOS ASOCIADOS CON EL DETERIORO COGNITIVO TAL COMO, PERO NO LIMITADO A MCI ("DETERIORO COGNITIVO LEVE"), LA ENFERMEDAD DE ALZHEIMER, PÉRDIDA DE MEMORIA, SÍNTOMAS DE DÉFICIT DE ATENCIÓN ASOCIADOS CON LA ENFERMEDAD DE ALZHEIMER, NEURODEGENERACIÓN ASOCIADA CON ENFERMEDADES TALES COMO LA ENFERMEDAD DE ALZHEIMER O LA DEMENCIA INCLUYENDO DEMENCIA DE ORIGEN VASCULAR Y DEGENERATIVO MIXTO, DEMENCIA PRE-SENIL, LA DEMENCIA SENIL Y LA DEMENCIA ASOCIADA CON LA ENFERMEDAD DE PARKINSON.
GT201300165A 2010-12-22 2013-06-20 Compuestos y su uso como inhibidores de bace GT201300165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425852P 2010-12-22 2010-12-22
US201161529620P 2011-08-31 2011-08-31

Publications (1)

Publication Number Publication Date
GT201300165A true GT201300165A (es) 2015-02-11

Family

ID=46314249

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300165A GT201300165A (es) 2010-12-22 2013-06-20 Compuestos y su uso como inhibidores de bace

Country Status (38)

Country Link
US (6) US8415483B2 (es)
EP (2) EP2655378B1 (es)
JP (3) JP6180325B2 (es)
KR (1) KR101916975B1 (es)
CN (2) CN106008355B (es)
AR (1) AR084553A1 (es)
AU (3) AU2011345389B2 (es)
BR (1) BR112013016030B1 (es)
CA (1) CA2822378C (es)
CL (1) CL2013001849A1 (es)
CO (1) CO6781485A2 (es)
CR (1) CR20130308A (es)
CY (1) CY1119211T1 (es)
DK (1) DK2655378T3 (es)
DO (3) DOP2013000147A (es)
EA (2) EA025746B9 (es)
EC (1) ECSP13012708A (es)
ES (2) ES2626727T3 (es)
GT (1) GT201300165A (es)
HR (1) HRP20170723T1 (es)
HU (1) HUE033274T2 (es)
LT (1) LT2655378T (es)
ME (1) ME02728B (es)
MX (1) MX342477B (es)
MY (1) MY178156A (es)
NI (1) NI201300055A (es)
NZ (2) NZ709235A (es)
PE (2) PE20141191A1 (es)
PL (1) PL2655378T3 (es)
PT (1) PT2655378T (es)
RS (1) RS55961B1 (es)
SA (2) SA111330107B1 (es)
SG (2) SG191127A1 (es)
SI (1) SI2655378T1 (es)
TW (2) TWI633092B (es)
UY (1) UY33829A (es)
WO (1) WO2012087237A1 (es)
ZA (1) ZA201305495B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US8779355B2 (en) 2011-12-28 2014-07-15 Quest Diagnostics Investments, Inc. Methods for detecting lacosamide by mass spectrometry
US9067926B2 (en) 2012-01-26 2015-06-30 Hoffmann-La Roche Inc. Fluoromethyl-5,6-dihydro-4H-[1,3]OXAZINES
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
SG11201407796YA (en) 2012-05-30 2014-12-30 Comentis Inc Chromane compounds
US9000185B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000183B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) * 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) * 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
EP2900650A1 (en) * 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US20140371283A1 (en) 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
CA3017418A1 (en) 2016-03-15 2017-09-21 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
TW201740944A (zh) 2016-03-15 2017-12-01 美國禮來大藥廠 組合療法
WO2017169503A1 (ja) * 2016-04-01 2017-10-05 国立大学法人 千葉大学 含窒素芳香族アミドの製造方法、ピロール・イミダゾールポリアミドの製造方法、及び化合物
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN107954927A (zh) * 2017-10-30 2018-04-24 广东莱佛士制药技术有限公司 一种3-溴-5-(丙炔-1-基)吡啶的制备方法
WO2019122268A1 (en) 2017-12-21 2019-06-27 Astrazeneca Ab Processes for the stereoselective preparation of bace inhibitors
WO2019122421A1 (en) 2017-12-22 2019-06-27 Astrazeneca Ab Stereoselective ketone reduction using a ketoreductase enzyme
WO2019129750A1 (en) 2017-12-29 2019-07-04 Astrazeneca Ab Processes for the racemization of dihydroimidazole ring systems
WO2019129755A1 (en) 2017-12-29 2019-07-04 Astrazeneca Ab Ketal hydrogenation
CN110615751B (zh) * 2018-06-19 2021-08-17 上海医药工业研究院 一种2-氧代硫代丙酰胺的制备方法
CN113573709A (zh) * 2019-03-14 2021-10-29 阿斯利康(瑞典)有限公司 用于体重减轻的兰比斯特
CN111253427A (zh) * 2020-03-13 2020-06-09 苏州大学 正丁基锂在催化醛和硅烷的氰硅化反应中的应用
CN114989103B (zh) * 2022-06-09 2024-07-09 杭州科巢生物科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (fr) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7915424B2 (en) 2004-03-22 2011-03-29 Eli Lilly And Company Pyridyl derivatives and their use as mGlu5 antagonists
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
CN101360716A (zh) 2005-11-21 2009-02-04 阿斯利康(瑞典)有限公司 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途
EP1966163A1 (en) 2005-12-21 2008-09-10 Boehringer Ingelheim International GmbH Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
CN101506162B (zh) * 2006-06-22 2012-06-27 阿斯利康(瑞典)有限公司 作为β位淀粉样前体蛋白裂解酶抑制剂的取代的异吲哚和它们的用途
WO2008076044A1 (en) * 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5, 5-diaryl-imidazol-4-ones
EP2108018A2 (en) * 2007-02-01 2009-10-14 Glaxo Group Limited 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
CN101809019A (zh) * 2007-05-07 2010-08-18 先灵公司 γ分泌酶调节剂
EP2249646A4 (en) 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
FR2929943B1 (fr) 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
CA2731209A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AU2009291602B2 (en) 2008-09-11 2013-02-14 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
NZ594230A (en) 2009-03-13 2013-11-29 Vitae Pharmaceuticals Inc Inhibitors of beta-secretase
AR077365A1 (es) 2009-07-02 2011-08-24 Astrazeneca Ab Derivados de imidazol para el tratamiento de enfermedades mediadas por la inhibicion de la formacion de abeta
UY32751A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
WO2012040641A2 (en) 2010-09-24 2012-03-29 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
WO2013054108A1 (en) 2011-10-10 2013-04-18 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt

Also Published As

Publication number Publication date
US20130210837A1 (en) 2013-08-15
AU2016200538A1 (en) 2016-02-18
WO2012087237A1 (en) 2012-06-28
DK2655378T3 (en) 2017-06-06
US8415483B2 (en) 2013-04-09
NZ709235A (en) 2016-11-25
SA114360153B1 (ar) 2015-11-29
HUE033274T2 (en) 2017-11-28
HRP20170723T1 (hr) 2017-07-28
LT2655378T (lt) 2017-06-12
BR112013016030A2 (pt) 2018-07-24
US8865911B2 (en) 2014-10-21
EA032687B1 (ru) 2019-07-31
US9248129B2 (en) 2016-02-02
AU2011345389A1 (en) 2013-08-01
EP3176172A1 (en) 2017-06-07
US10231967B2 (en) 2019-03-19
DOP2017000030A (es) 2017-02-28
EA201390830A1 (ru) 2013-12-30
MX342477B (es) 2016-09-30
ES2626727T3 (es) 2017-07-25
KR101916975B1 (ko) 2018-11-08
EA025746B9 (ru) 2017-06-30
ECSP13012708A (es) 2013-08-30
JP2017008072A (ja) 2017-01-12
CL2013001849A1 (es) 2013-12-20
NZ612041A (en) 2015-07-31
KR20130143629A (ko) 2013-12-31
ME02728B (me) 2017-10-20
AU2017261475A1 (en) 2017-11-30
PE20141191A1 (es) 2014-09-21
EP2655378B1 (en) 2017-03-01
BR112013016030B1 (pt) 2022-03-29
US20150133471A1 (en) 2015-05-14
US20170319578A1 (en) 2017-11-09
SI2655378T1 (sl) 2017-06-30
CN106008355A (zh) 2016-10-12
JP2014504300A (ja) 2014-02-20
CN103380133A (zh) 2013-10-30
CN106008355B (zh) 2019-05-03
EP3176172B1 (en) 2020-01-29
DOP2013000147A (es) 2013-10-15
US20160184303A1 (en) 2016-06-30
UY33829A (es) 2012-07-31
PT2655378T (pt) 2017-05-29
EA201690787A1 (ru) 2017-02-28
SG191127A1 (en) 2013-07-31
JP2018083840A (ja) 2018-05-31
CA2822378A1 (en) 2012-06-28
JP6180325B2 (ja) 2017-08-16
TW201716386A (zh) 2017-05-16
CY1119211T1 (el) 2018-02-14
EA025746B1 (ru) 2017-01-30
AU2016200538B2 (en) 2017-08-31
ES2780928T3 (es) 2020-08-27
TWI633092B (zh) 2018-08-21
JP6527255B2 (ja) 2019-06-05
US20120165347A1 (en) 2012-06-28
AR084553A1 (es) 2013-05-22
ZA201305495B (en) 2016-07-27
TWI618700B (zh) 2018-03-21
SA111330107B1 (ar) 2015-03-26
EP2655378A1 (en) 2013-10-30
PL2655378T3 (pl) 2017-09-29
DOP2016000191A (es) 2016-09-15
NI201300055A (es) 2014-03-07
CO6781485A2 (es) 2013-10-31
CR20130308A (es) 2014-02-13
MX2013007319A (es) 2013-07-22
CN103380133B (zh) 2016-06-29
RS55961B1 (sr) 2017-09-29
SG10201602241SA (en) 2016-04-28
US9918985B2 (en) 2018-03-20
CA2822378C (en) 2020-01-14
US20180221367A1 (en) 2018-08-09
EP2655378A4 (en) 2014-07-09
AU2011345389B2 (en) 2015-10-29
JP6333317B2 (ja) 2018-05-30
MY178156A (en) 2020-10-06
PE20171342A1 (es) 2017-09-13
TW201302713A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
GT201300165A (es) Compuestos y su uso como inhibidores de bace
NZ603789A (en) Heteroaryl compounds and methods of use thereof
ECSP11011051A (es) Nuevos compuestos 578
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
IN2014DN03206A (es)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
IN2013CN01340A (es)
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
IN2012DN01233A (es)
IN2014KN01075A (es)
MX2013003034A (es) Lactamas piperidinilo-substituidas como moduladores de gpr119.
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
IN2015DN00345A (es)
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
MX2010008707A (es) Composiciones farmaceuticas de entacapona comicronizada con alcoholes de azucar.
CU20130083A7 (es) Compuestos y su uso como inhibidores de bace
MX2009012711A (es) Uso de 4-fenil-imidazol-2-tionas como inhibidores de la tirosinasa, para la preparacion de composiciones farmaceuticas o cosmeticas destinadas al tratamiento o la prevencion de trastornos pigmentarios.
UA109918C2 (xx) Спіропохідні аміноімідазолів та їх застосування як bace-інгібіторів